The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia. Issue 33 (25th November 2013)

• Record Type: Journal Article
• Authors: Carver, Alissa R.; Tamayo, Esther; Perez‐Polo, J. Regino; Saade, George R.; Hankins, Gary D.V.; Costantine, Maged M.
• Is Part Of: International journal of developmental neuroscience. Issue 33(2014:Apr.)
• Page Start: 33
• Page End: 40
• Publication Date: 2013-11-25
• Subjects: Fetal programming -- Pravastatin -- Preeclampsia -- Soluble Fms‐like tyrosine kinase 1 -- Neuromotor function; Developmental neurobiology -- Periodicals; Neurology -- Periodicals; Neurologie du développement -- Périodiques; Developmental neurobiology; Periodicals; 612.8
• DOI: 10.1016/j.ijdevneu.2013.11.004
• Languages: English
• ISSNs: 0736-5748

Abstract

Abstract: Animal and human studies show that in‐utero exposure to preeclampsia alters fetal programming and results in long‐term adverse cardiovascular outcomes in the offspring. Human epidemiologic data also suggest that offspring born to preeclamptic mothers are also at risk of adverse long term neurodevelopmental outcomes. Pravastatin, a hydrophilic lipid‐lowering drug with pleiotropic properties, was found to prevent the altered cardiovascular phenotype of preeclampsia and restore fetal growth in animal models, providing biological plausibility for its use as a preventive agent for preeclampsia. In this study, we used a murine model of preeclampsia based on adenovirus over‐expression of the anti‐angiogenic factor soluble Fms‐like tyrosine kinase 1, and demonstrated that adult offspring born to preeclamptic dams perform poorly on assays testing vestibular function, balance, and coordination, and that prenatal pravastatin treatment prevents impairment of fetal programming.